8-K: Sangamo Therapeutics Reports Positive Topline Results for Fabry Disease Gene Therapy ST-920, Paving Way for Accelerated Approval Pathway

Sangamo Therapeutics announced highly positive topline results from its registrational Phase 1/2 STAAR study for isaralgagene civaparvovec (ST-920), a wholly owned investigational gene therapy for Fabry disease, demonstrating significant clinical benefits and a favorable safety profile.

Summary

• Sangamo Therapeutics announced positive topline results from the registrational Phase 1/2 STAAR study evaluating isaralgagene civaparvovec (ST-920), an investigational gene therapy for adults with Fabry disease.
• A positive mean annualized eGFR slope of 1.965 mL/min/1.73m²/year (95% CI: -0.153, 4.083) was observed at 52-weeks across all 32 dosed patients, which the FDA has agreed will serve as an intermediate clinical endpoint under the Accelerated Approval pathway.
• For the 19 patients with 104-weeks of follow-up, a mean annualized eGFR slope of 1.747 mL/min/1.73m²/year (95% CI: -0.106, 3.601) was observed.
• The observed eGFR slopes compare favorably to estimated mean annualized eGFR slopes for other marketed Fabry disease treatments, which range from -2.2 to -0.4 mL/min/1.73m²/year.
• Elevated expression of alpha-galactosidase A (-Gal A) activity was maintained for up to 4.5 years in the longest treated patient.
• All 18 patients who began the study on enzyme replacement therapy (ERT) have been successfully withdrawn from ERT and remain off ERT.
• Plasma lyso-Gb3 levels in ERT-withdrawn patients remained generally stable, and stabilization in cardiac endpoints was also observed.
• Patients showed improvements in disease severity (FOS-MSSI age-adjusted score) and statistically and clinically significant improvements in SF-36 quality of life scores, including role-physical (+14.8), vitality (+9.6), and physical component scores (+4.2) at week 52 compared to baseline.
• Statistically significant improvements in the gastrointestinal symptoms rating scale (GSRS) were also observed.
• Additional clinical benefits included reduction or elimination of pain medication usage and resumption of sweating in some patients.
• Isaralgagene civaparvovec demonstrated a favorable safety and tolerability profile without the requirement for preconditioning; the majority of adverse events were Grade 1-2 and resolved.
• Common treatment-emergent adverse events (TEAEs) included pyrexia (60.6%), COVID-19 (36.4%), headache (33.3%), and nasopharyngitis (33.3%).
• There were no safety-related study discontinuations.
• Sangamo believes these data support the potential for ST-920 as a one-time, durable treatment for Fabry disease and will form the basis for an anticipated Biologics Licensing Application (BLA) submission as early as the first quarter of 2026.
• ST-920 has received Orphan Drug, Fast Track, and RMAT designations from the FDA, Orphan Medicinal Product and PRIME eligibility from the EMA, and Innovative Licensing and Access Pathway from the U.K. MHRA.

Sentiment

Score: 9

Explanation: The document reports highly positive topline clinical trial results for a gene therapy targeting Fabry disease, demonstrating significant improvements in key endpoints and a favorable safety profile, positioning it as a potentially superior one-time treatment. The company is preparing for BLA submission and commercialization discussions. However, the forward-looking statements section highlights risks related to capital resources and the need for additional funding, which slightly tempers the overall sentiment.

Positives

• Positive mean annualized eGFR slope of 1.965 mL/min/1.73m²/year at 52-weeks and 1.747 mL/min/1.73m²/year at 104-weeks, significantly better than the negative or near-zero slopes observed for approved treatments (ranging from -2.2 to -0.4 mL/min/1.73m²/year).
• FDA agreement on eGFR slope as an intermediate clinical endpoint for the Accelerated Approval pathway.
• Maintained elevated alpha-galactosidase A activity for up to 4.5 years in the longest treated patient.
• All 18 patients who were on ERT successfully withdrew from therapy and remain off ERT, indicating a potential for a one-time treatment.
• Stable plasma lyso-Gb3 levels observed following ERT withdrawal.
• Stabilization in cardiac endpoints was observed.
• Improvements in disease severity reported in the Fabry Outcome Survey adaptation of the Mainz Severity Score Index (FOS-MSSI) age-adjusted score.
• Statistically and clinically significant improvements in multiple short form-36 (SF-36) quality of life scores, including role-physical (+14.8), vitality (+9.6), bodily pain (+9.0), social functioning (+7.8), general health (+7.4), and physical component scores (+4.2) at week 52 compared to baseline.
• Statistically significant improvements in the gastrointestinal symptoms rating scale (GSRS) compared to baseline.
• Observed additional clinical benefits in some patients, such as reduction or elimination of pain medication usage and resumption of sweating.
• Favorable safety and tolerability profile without the requirement for preconditioning.
• The majority of adverse events were mild (Grade 1-2) and resolved in response to clinical management.
• No safety-related study discontinuations occurred.
• Received multiple important regulatory designations: Orphan Drug, Fast Track, and RMAT from the FDA; Orphan Medicinal Product designation and PRIME eligibility from the European Medicines Agency; and Innovative Licensing and Access Pathway from the U.K. Medicines and Healthcare products Regulatory Agency.

Negatives

• The most common treatment-emergent adverse events (TEAEs) were pyrexia (60.6% of participants), COVID-19 (36.4%), headache (33.3%), and nasopharyngitis (33.3%), although these were generally mild (Grade 1-2) and resolved.

Risks

• Sangamo's lack of capital resources to obtain regulatory approval for and commercialize its product candidates in a timely manner or at all.
• Inability to secure a collaboration partner for ST-920.
• Uncertain timing and unpredictable nature of clinical trial results, including the risk that preliminary or topline data is not indicative of final results.
• Risk that the therapeutic effects observed in the latest preliminary clinical data from the Phase 1/2 STAAR study will not be durable in patients.
• Risk that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene civaparvovec.
• Risk that the 52-week data from the Phase 1/2 STAAR study will not support a BLA submission and/or that the 104-week data will not verify the clinical benefit or support FDA approval.
• Risk that patients withdrawn from ERT will not remain off ERT.
• Sangamo's need for substantial additional funding to execute its operating plan and to continue to operate as a going concern.
• The effects of macroeconomic factors or financial challenges on the global business environment, healthcare systems, and Sangamo's business and operations.
• Risks inherent in the research and development process.
• The unpredictable regulatory approval process for product candidates across multiple regulatory authorities.
• The potential for technological developments that obviate technologies used by Sangamo.
• Sangamo's reliance on collaborators and its potential inability to secure additional collaborations.
• Sangamo's ability to achieve expected future financial performance.

Future Outlook

Sangamo Therapeutics intends to submit a Biologics Licensing Application (BLA) for isaralgagene civaparvovec under the Accelerated Approval pathway as early as the first quarter of 2026. The company is also advancing BLA preparation activities and continuing business development negotiations for a potential Fabry commercialization agreement. Additional data from the STAAR study will be presented at an upcoming medical meeting.

Management Comments

• Sangamo believes the totality of these data supports the potential for isaralgagene civaparvovec as a one-time, durable treatment for Fabry disease that can improve patient outcomes and will form the basis for an anticipated Biologics Licensing Application (BLA) submission under the Accelerated Approval pathway as early as the first quarter of 2026.

Industry Context

This announcement is significant for the rare disease and gene therapy sectors, particularly for Fabry disease. The positive clinical results for ST-920 suggest a potential paradigm shift from chronic enzyme replacement therapies (ERTs) and oral chaperones to a one-time gene therapy. If approved, ST-920 could offer a more convenient and potentially more effective treatment option, addressing a high unmet medical need for patients seeking durable solutions beyond lifelong infusions or daily pills. The favorable eGFR slope and successful ERT withdrawal demonstrate a competitive advantage over existing treatments.

Comparison to Industry Standards

• Isaralgagene civaparvovec (ST-920) demonstrated a positive mean annualized eGFR slope of 1.965 mL/min/1.73m²/year at 52-weeks and 1.747 mL/min/1.73m²/year at 104-weeks.
• This compares favorably to observational studies of currently approved treatments for Fabry disease:
• Replagal (agalsidase alfa) has an estimated mean annualized eGFR slope of -2.2 mL/min/1.73m²/year in male patients and -0.7 mL/min/1.73m²/year in female patients.
• Fabrazyme (agalsidase beta) has an estimated mean annualized eGFR slope of -1.5 mL/min/1.73m²/year.
• Galafold (migalastat) has an estimated mean annualized eGFR slope of -0.4 mL/min/1.73m²/year.
• The ability of ST-920 to allow all 18 patients who started on ERT to successfully withdraw and remain off therapy, while maintaining stable plasma lyso-Gb3 levels, highlights its potential as a durable, one-time treatment, a significant advantage over chronic ERT or oral chaperone regimens.

Stakeholder Impact

• Shareholders: Highly positive clinical results could significantly increase share value due to the potential for accelerated market approval and commercialization of a breakthrough therapy. However, the disclosed need for substantial additional funding or a collaboration partner introduces a risk of future dilution.
• Patients with Fabry disease: The potential for a one-time, durable gene therapy that significantly improves kidney function, quality of life, and allows for withdrawal from chronic ERT represents a major advancement and improved treatment option.
• Employees: Positive clinical progress and potential market entry could lead to increased job security, growth opportunities, and a more stable company outlook.
• Competitors (e.g., companies producing Replagal, Fabrazyme, Galafold): The introduction of a potentially superior, one-time gene therapy could pose a significant competitive threat to their existing market share for Fabry disease treatments.

Next Steps

• Perform a meta-analysis of published studies to compare the annualized mean eGFR slope of isaralgagene civaparvovec with approved treatments for Fabry disease.
• Present analyses of the full dataset from the STAAR study at an upcoming medical meeting.
• Advance Biologics Licensing Application (BLA) preparation activities for isaralgagene civaparvovec.
• Engage in business development negotiations for a potential Fabry commercialization agreement.
• Anticipated BLA submission for isaralgagene civaparvovec as early as the first quarter of 2026.

Key Dates

Recommendation

Keywords

Sangamo Therapeutics, ST-920, isaralgagene civaparvovec, Fabry disease, gene therapy, rare disease, clinical trial, Phase 1/2 STAAR study, eGFR, alpha-galactosidase A, ERT withdrawal, FDA Accelerated Approval, Biologics Licensing Application, Orphan Drug, Fast Track, RMAT, biotechnology, pharmaceuticals